Abstract. Platelet membrane glycoprotein IIb-IIIa forms a calcium-dependent heterodimer and constitutes the fibrinogen receptor on stimulated platelets. GPIIb is a two-chain protein containing disulfide-linked ~t and 13 subunits. GPIIIa is a single chain protein. These proteins are synthesized in the bone marrow by megakaryocytes, but the study of their synthesis has been hampered by the difficulty in obtaining enriched population of megakaryocytes in large numbers. To examine the biosynthesis and processing of GPWo-IIIa, purified human megakaryocytes were isolated from liquid cultures of cryopreserved lenkocytes stem cell concentrates from patients with chronic myelogenous leukemia. Immunoprecipitation of [35S]methionine pulse-chase-labeled cell extracts by antibodies specific for the tx or 13 subunits of GPIIb indicated that GPIIb was derived from a precursor of Mr 130,000 that contains the tx and 13 subunits. This precursor was converted to GPIIb with a half-life of 4-5 h. No precursor form of GPHIa was detected. The glycosylation of GPI~-IIIa was examined in megakaryocytes by metabolic labeling in the presence of tunicamycin, monensin, or treatment with endoglycosidase H. The polypeptide backbones of the GPIIb and the GPIIIa have molecular masses of 120 and 90 kD, respectively. High-mannose oligosaccharides are added to these polypeptide backbones co-translationally. The GPIIb precursor is then processed with conversion of highmannose to complex type carbohydrates yielding the mature subunits GPIIb0t (M~ 116,000) and GPI]bl3 (Mr 25,000). No posttranslational processing of GPRIa was detected. p LATELET GPIIb-Ula is a calcium-dependent heterodimer making up 18% of the platelet membraneassociated glycoproteins (12). GPHb is composed of two disulfide-linked polypeptide chains: IIbct and IIb13 of apparent molecular masses, on SDS gel electrophoresis, of 116 and 25 kD, respectively (12, 18). GPIIIa is a single chain polypeptide which has an apparent molecular mass of 100 kD when reduced (12). GPIlb-HIa is implicated in the platelet adhesive reactions. It serves as a receptor for fibrinogen (16), fibronectin (19), and von Willebrand factor (25), these interactions being essential for platelet attachment, spreading, and aggregation. Recently, two observations have suggested that GPIlb-RIa is a member of a broadly distributed family of membrane adhesion receptors which mediate cell adhesion and cell-cell interactions, and for which the designation "cytoadhesins" has been proposed. Firstly, the presence of antigens related to GPIIb-lIIa on the surface of ceils other than platelets has been demonstrated. Certain monoclonal and polyclonal antibodies which interact with the platelet GPl/b-IIIa immunoprecipitate similar species from surface-labeled endothelial cells (8) and leukocytes (6). Secondly, GPHb-IBa recognizes Arg-Gly-Asp-containing sequences (22), and is thus a member of the widely distributed family of Arg-Gly-Asp-binding receptors (20, 21) . Differences in receptor specificity and in the molecular mass of the constituent subunits of these receptors have been observed according to their cellular origin, suggesting that the differences amongst these proteins may result from the transcription of distinct genes. Alternatively, the subunits of these receptors may derive from a single gene via cell-specific posttranscriptional processing mechanisms. The recent c~b-servation that a 20-kb genomic fragment (7) appears to contain sequences encoding proteins immunologically related to GPIlb-IIIa as well as to OKM-1 and LFA-1, two other membrane adhesion receptors expressed in leukocytes, is in support of the latter hypothesis. The analysis of the posttranscriptional events which occur during the biosynthesis and processing of these adhesion receptors should provide a valuable insight into the molecular mechanisms which control the expression of these receptors at the surface of these different cell types.
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GPIIb-IIIa synthesis is detectable from the early stages of megakaryocytopoiesis (31). As the megakaryocyte represents less than 0.5 % of all bone marrow cells and is difficult to purify in large quantities, information on the cellular transit of GPIIb-IIIa in human megakaryocytes has not as yet been available. Recently we have described the isolation of human megakaryocytes from liquid culture of cryopreserved leukocytes stem cells concentrates from patients with chronic myelogenous leukemia (CML) 1 (3) . High numbers of developing megakaryocytes from the megakaryoblast to the polyploid mature megakaryocyte can be obtained in these liquid cultures (4). These cells have been shown to express not only platelet GPIIb-IIIa but also fibrinogen, von Willebrand factor, and GPIb, which are either not expressed or only weakly expressed in established erythroblastic cell lines. Thus, these megakaryocytes constitute an excellent tool for studying the specific nuclear and cytoplasmic mechanisms controlling the biosynthesis and processing of platelet factors. In this study, these cells have been used to examine the biosynthesis and processing of GPIIb-IIIa.
Materials and Methods

Materials
Carrier-free t~I (17 laCi/mg) and [35S]methionine (1,000 mCi/mmol) Amplifier and molecular mass standards were from Amersham International (Amersham, England). P2, an anti-GPllb-ma monoclonal antibody (17) was obtained from Immunotech (Marseille, France). BSA, monensin, tunicamycin, Staphylococcus aureus Cowan I strain (Pansorbin) and lactoperoxidase were from Calbiochem-Behring Corp. (La Jolla, CA). OligodT cellulose was obtained from Bethesda Research Laboratories (Bethesda, MD) and endoglycosidase H (endo H) was from New England Nuclear (Boston, MA). The nuclease-treated rabbit reticulocyte lysate system was from Promega Biotec (Madison, WI). The immunoblot assay kit used for Western blotting was from Bio-Red Laboratories (Richmond, CA).
Purification of Human Megakaryocytes
Megakaryocytes were obtained from liquid cultures of cryopreserved blood cell concentrates from patients in the chronic phase of CML as previously described (3, 4) . Briefly, leukocytes-enriched fractions were obtained from CML patients by leukophoresis, and the leukocytes were separated from platelets by low-speed centrifugation at 300 g for 10 min. The leukocyte pellet was washed twice in Hanks' balanced salt solution (HBSS). Low-density cells containing the megakaryoeytic progenitor cells were obtained after centrifugation on a BSA density gradient and stored at -1960C using a twostep freezing technique, as previously described (2) . Culturing of thawed cells was performed in T 25 flasks (Falcon Labwares, Oxnard, CA) with 5 x 106 cells per 10 ml RPMI 1640 medium supplemented with 20% human plasma. Incubation was performed at 370C in a 5% CO2 fully humidified atmosphere.
GPIIb-IIIa-positive ceils were purified by sorting on a fluorescenceactivated cell sorter (FACS IV, Becton Dickinson, Mountain View, CA) equipped with a 5-W argon ion laser (Spectra-Physics Inc., Mountain View, CA). Cells were labeled by indirect immunofluorescence using P2, a monoclonal antibody which reacts with GPIlb-IHa (17) . The purity of the sorted cell population was evaluated using standard cytological criteria for megakaryocytic cells (32) . After sorting, the cells were cultured in human plasma-supplemented RPMI medium for 24 h before use.
Labeling Procedures
Metabolic labeling of proteins synthesized by the cultured human megakaryocytes was routinely performed in 35-mm plastic dishes containing 2 × 106 cells/ml in methionine-free RPMI 1640 with 20% dialyzed human plasma and 250 ttCi. [35S]Methionine was then added and the cells were incubated for up to 8 h at 3"/°C in an atmosphere of 95% air/5% CO2. For pulse-chase experiments, cells were initially labeled as above for 30 min with 250 IxCi/ml [35S]methionine, and the pulse was terminated by removing the [35S]methionine-containing medium. The cells were washed twice with HBSS and incubated with the media containing 20% human plasma for intervals of up to 48 h. When labeling was performed in the presence of tunicamycin or monensin, the cells were preincubated at 37"C with 1. Abbreviations used in this paper: CML, chronic myelogenous leukemia; endo H, endoglycosidase H. either 5 ~tg/ml tunicamycin for 2 h or with 2 lag/ml monensin for 16 h. The drug concentrations were maintained throughout the incubation with [35S]methionine.
Washing and Surface Iodination of Platelets
Platelets were isolated from acid citrate dextrose anti-coagulated fresh human blood by differential centrifugation and gel filtration as previously described (16) . The platelets were ultimately suspended in Tyrode's buffer containing 2 % BSA and tested for aggregation and fibrinogen binding using previously described assay systems (15) . Washed platelets were surface labeled in the presence of carder-free J:5I using the lactoperoxidase method
(18).
Antibodies
A454 is a goat polyclonal antibody raised against a purified preparation of platelet GPIIb-IIla. Two rabbit antibodies were raised against purified GPIFott and GPIIbl3 subunits from human platelets. To purify the two subunits, platelet membrane extracts were applied to a Sepharose affinity column to which CS9, a monoclonal antibody specific for GPIIb-IIIa produced in our laboratory, had been coupled. A fraction containing GPIIb-IIIa was ehited with EDTA at pH 8.9 at 37°C and subjected to electrophoresis on an exponential 5-20% gradient polyacrylamide gel, under reduced conditiom. Electrophoretic bands at 116 and 25 kD corresponding to GPI~a and GPIlb[3 were excised, and specific antibodies were prepared by subcutaneous injection of rabbits with 20-100 lag of purified subunit emulsified in complete Freund's adjuvant. The rabbits were given a booster injection 2 wk later with the protein in incomplete adjuvant and then bled 2 wk after the last injection. Monoclonal antibodies, 22C4 and PMI-1, which specifically recognize GPIIIa and GPIIbet, respectively, have been previously described (9, 26) .
The specificities of A454, PMI-1, and 22C4 wore tested by immunoprecipitation of lactoperoxidase surface-labeled platelet extract and gel electrophoresis. The specificities of the polyclonal antibodies anti-GPIIbct and anti-GPllb[$ were analyzed by Western blot. Briefly, 10 lag of proteins from a 1% Triton X-100 platelet extract were subjected to electrophoresis on a 7-12 % linear gradient acrylamide gel with or without reduction with 5 % 2-mercaptoethanol. Proteins were transferred onto a nitrocellulose filter, the strips incubated with the antisera at a 1:100 dilution for 1 h, and the antibodies detected using an immunoperoxidase method.
Preparation of Cell Lysates and Immunoprecipitation
After labeling, the cells were washed twice with ice-cold PBS and lysed with lysis buffer (1% Triton X-100 and 2 mM phenylmethylsulfonyl fluoride [PMSF] in PBS, pH 7.4) for 20 min on ice. The lysate was clarified by centrifngation at 11,000 g for 10 rain. 1 ml of cell extract was treated with 100 lal of a 10% Staphylococcus aureus Cowan I strain suspension for 30 min at 4°C. The Pansorbin was removed by centrifugation and 100 ~tl of the cell lysate diluted with 4 vol of washing buffer (1% Triton X-100, 0.5% SDS, 0.5% sodium deoxycholate, 0.5% BSA in PBS, pH 7.4) and incubated for 16 h at 4°C with 5-20 lal of specific antibodies against GPIIb and GPIIIa. The immunoprecipitate was washed twice with I ml washing buffer and then eight times with washing buffer without BSA. After the washing steps, the adsorbed immune complexes were dissociated by boiling for 5 min at 100°C in 50 mM Tris-HCl, pH 6.8, containing 5% mercaptoethanol, 2% SDS, 10% glycerol, and 0.01% bromophenol blue. The samples were clarified by centrifugation at 11,000 g for 5 rain and analyzed by SDS-PAGE on either 7. 5 % gels or linear gradient gels of 7-12 %, according to Laemmli (14) . After electrophoresis, the gels were fixed for 30 min with 7 % acetic acid and treated with Amplify for 30 min, dried under vacuum at 80°C, and exposed to Kodak X-O Mat film at -70°C, using Dupont Cronex Lighting Plus intensifying screens.
Treatment of Proteins with Endo H
35S-labeled proteins were isolated by immunoprecipitation with antiserum A454, and fractionated by SDS-PAGE as described above. The [35Slme-thionine-labeled bands, detected by autoradiography, were excised from the gels using the autoradiograph film as a template. Sample buffer containing SDS and 5% 2-mercaptoethanol was added to each band, and the gel was then crushed. Digestions with endo H were performed in the presence of 0.1 M sodium citrate buffer (pH 5.5) containing 2 mM PMSF and 7 gg/ml of the enzyme. After 18 h of incubation, the reaction was stopped by heating for 2 rain at 100°C.
Preparation of m R N A and Cell-Free Translation
Total RNA was isolated from cells using the guanidin-hydrochloride method (13) in the presence of ianrylsarkosine. Poly (A)-rich RNA was isolated by oligo-dT cellulose chromatography of total RNA (1). 4 ~tg of Poly (A) + mRNA were incubated with [35S]methionine (2 mCi/ml) and reticulocyte lysate for 90 min at 30°C in a total volume of 100 ~tl. After incubation, PMSF was added at a final concentration of 2 mM and incorporation of radioactivity in the translation assay was determined by removing l-l, tl aliquots and measuring the radioactivity precipitated by 10% TCA.
Results
Specificity of the Antibodies
The specificity of these antibodies is demonstrated in Fig. 1 . On immunoprecipitation of lactoperoxidase surface-labeled Figure 1 . Specificity of antibodies against platelet GPIIb and GPIIIa. (A) Surface-iodinated washed platelets were lysed in PBS containing 1% Triton X-100 and 2 mM PMSE An aliquot of this extract (2 × 106 cpm) was incubated with 10 Ill of the selected antibody and 100 lal of 10% Staphylococcus aureus Cowan I (see Materials and Methods). The immunoprecipitate was subjected to electrophoresis on a 7.5% polyacrylamide gel under reducing conditions. Display of t25I was monitored by autoradiography of the dried gels. platelet extract and gel electrophoresis under reduced conditions, A454 precipitated bands at 116 and 100 kD ( Fig. 1 A, lane 1) and monoclonal antibodies 22C4 and PMI-1 bands at 100 and 116 kD, respectively ( Fig. 1 A, lanes 2 and 3) . By Western blotting, the antibody anti-GPIIba recognized electrophoretic bands at 130 (nonreduced) and 116 (reduced) kD ( Fig. 1 B, lanes 1 and 2) , while the antibody anti-GPIIbl3 blotted electrophoretic bands at 130 (nonreduced) and 25 (reduced) kD ( Fig. 1 B, lanes 3 and 4) .
Characterization of Purified Megakaryocytes
Large numbers of megakaryocytes were obtained in liquid cultures of cryopreserved blood cell concentrates from patients in the chronic phase of CML (3, 4) . The thawed blood Fig. 2 B. After purification, the megakaryocytes were cultured for an additional 24 h in human plasma-supplemented RPMI at a cell density of 1 x 106 per ml. The cytological composition of a megakaryocyte preparation before and after sorting is illustrated in Table I . The sorted cell suspension contained <10% myeloid and macrophagic cells, the major contaminating cells in these CML leukocyte cultures.
Analysis of GPIIb and GPIIIa Produced by Human Megakaryocytes
A series of experiments were performed to identify and characterize the GPIIb-and GPIIIa-related proteins produced by the purified megakaryocytes. Initially, the cells were metabolically labeled with [35S]methionine for 8 h and the immunoreactive species precipitated from cell lysates with the various antisera and analyzed by SDS-PAGE under reducing conditions. The results are summarized in Fig. 3 A. Three major electrophoretic bands with estimated molecular masses of 130, 116, and 100 kD (reduced) were detected in the immunoprecipitates of the polyclonal anti-GPIIb-IIIa A454 (Fig. 3 A, lane 1) . Monoclonal antibody 22C4, specific for GPIIIa, immunoprecipitated a protein at 100 kD ( Fig. 3 A, lane 2) , while the monoclonal PMI-1, specific for GPIIbct, immunoprecipitated bands at 130 and 116 kD (Fig.  3 A, lane 3) . Controls of nonimmune goat IgG and nonimmune ascite were performed replacing the A454 or the monoclonal antibodies, respectively. No bands were detected in these controls. Fig. 3 A, lane 4, shows the nonimmune goat IgG control. Furthermore, immunocompetitive experiments with the polyclonal antibody in the presence of a large excess of cold platelet membrane extracts resulted in the loss of detectable bands after SDS-PAGE. The immunoprecipitate obtained with A454 has been compared under reducing and nonreducing conditions in Fig. 3 B. After 8 h of metabolic labeling, A454 precipitated three major bands at 130, 116, and 100 kD, under reducing conditions ( Fig. 3 B, lane 1 ) . When the immunoprecipitate was run under nonreducing conditions, bands at 130, 120, and 90 kD were detected (Fig. 3 B, lane 2) . To identify the mature forms of GPIIb and GPIIIa produced by the megakaryocytes, the cells were labeled with [35S]methionine for 8 h followed by an incubation in normal cold medium for 72 h. Under these conditions two electrophoretic bands were immunoprecipitated by A454 with apparent molecular masses of 116 and 100 kD (reduced) and 130 and 90 kD (nonreduced) (Fig. 3 B,  lanes 3 and 4) . The two electrophoretic bands with apparent molecular masses of 130 and 90 kD under nonreducing conditions were excised, reduced with 5 % 2-mercaptoethanol, and reanalyzed separately on a 7-12 % linear polyacrylamide gel. Under these conditions, the 130-kD protein resolved into two subunits of 116 and 25 kD (Fig. 3 C, lane 1) . When the protein at 90 kD was reduced it migrated as a 100-kD species (Fig. 3 C, lane 2) . Due to (a) similarities in electrophoretic properties and estimated molecular masses with those previously reported for reduced and nonreduced GPIIb and GPIIIa, (b) the selective immunoprecipitation of electrophoretic bands with specific monoclonal antibodies, and (c) neutralization of the immunoprecipitation by proteins from platelet membranes, it was concluded that the band at 100 kD was the reduced form of GPIIIa having an apparent molecular mass of 90 kD when nonreduced. The electrophoretic band at 116 kD was the reduced form of GPIIba which when nonreduced has an apparent molecular mass of 130 kD. The electrophoretic band at 130 kD (reduced) which was specifically recognized by the monoclonal anti-GPIIb presumably represents a precursor form of the GPIIb. Under nonreducing conditions this pro-GPIIb has an apparent molecular mass of 120 kD (Fig. 3 B, lane 2) . This hypothesis was confirmed in subsequent pulse-chase experiments.
P u l s e -C h a s e Kinetic A n a l y s i s
Posttranslational modifications of GPIIb and GPIIIa were examined in pulse-chase experiments. Megakaryocytic cells were pulsed with [35S]methionine for 30 min and chased with cold culture medium for 0 to 48 h. The immunoreactive forms of GPIIb and GPIIIa were precipitated with A454 and analyzed on SDS-polyacrylamide gels under reducing conditions (Fig. 4 A) . Immediately after the 30-min pulse (0 h of chase), two bands at 130 and 100 kD were obtained. Densitometric scanning of the autoradiograms indicated that the intensity of the 100 kD band did not change significantly over the subsequent 48 h, while the band at 130 kD decreased in intensity with a half-life of 4-5 h (Fig. 4 B) . Simultaneously the appearance and intensification of the 116 and 25 kD electrophoretic bands was observed. These bands were first detected after 1 to 2 h, while 48 h was required for the complete disappearance of the pro-GPIIb. Short-term pulse-chase experiments (10-min pulse and 30-min chase) were performed to detect possible early posttranslational events in the biosynthesis, but none were observed.
The Pro-GPllb Contains GPIIbQ and GPIIbf3 Subunits
Definitive evidence that the 130-kD band represented a precursor form of GPIIb containing both the ¢t and [3 subunits of mature GPIlb was obtained by immunoprecipitation with antisera specific for each subunit. As shown in Fig. 4 C, when the cell lysate was first reduced and alkylated, the anti-GPIII3 immunoprecipitated the band at 130 kD and a protein of 25 kD corresponding to the GPIIb[~ subunit (lane 1), while the anti-GPIIbct immunoprecipitated the two bands of 130 and 116 kD. This result demonstrates that the specific anti-GPHbl~ immunoprecipitated the pro-GPIlb confirming the presence of GPIIb[3 epitopes on the precursor form of GPIIb.
Endo H Treatment of the Different Forms of GPIIb and GPIIIa
The nature of the oligosaccharide side chains present on the different molecular forms of GPIIb and GPIIIa produced by megakaryocytes was then investigated by examining their resistance to endo H. This enzyme removes unprocessed highmannose oligosaccharide side chains from glycoproteins but does not cleave fully processed oligosaccharide side chains (28) . The 130-, 116-, and 100-kD bands obtained by immunoprecipitation with A454 from [3SS]methionine-labeled cells were excised and treated with 7 0g/ml endo H for 16 h and reelectrophoresed on 7.5% SDS-polyacrylamide gels. The fluorograms depicted in Fig. 5 A show that the mobilities of the 130-and 100-kD bands were altered while the protein of 116 kD was resistant to endo H. Deglycosylation of the proGPIIb form changed its estimated molecular mass from 130 to 120 kD. The 120-kD protein was immunoprecipitated from a cell-free translation system programmed with megakaryocytic mRNA using both A454 and the monoclonal antiGPIIb~t, PMI-1 (Fig. 5 B, lanes 2 and 3) . A minor band of low molecular mass can be seen, possibly representing incompletely translated peptides. Thus the 120-kD protein, derived from the 130-kD species by endo H treatment, probably represents fully deglycosylated pro-GPllb. The GPIIIa species, produced by the megakaryocytes, was also sensitive to endo H. Treatment by this enzyme reduced its apparent molecular mass from 100 to 90 kD under reducing conditions.
Effect of Glycosylation on the Processing of GPIIb and GPIIIa
Tunicamycin, an antibiotic which blocks co-translational addition of N-linked oligosaccharide to the growing polypeptide (30) affected GPIlb and GPIIIa processing. Fig. 6 A shows that tunicamycin inhibited the formation of the 130-, 116-, and 100-kD bands and two major proteins of 120 and 90 kD were immunoprecipitated. In the presence of tunicamycin, some minor bands were observed and represent nonspecific immunoprecipitated proteins.
Monensin which blocks the processing of N-linked oligosaccharides from high-mannose to the complex type in the Golgi cisternae (27, 29) , also affected GPIIb biosynthesis (Fig. 6 B) . Immunoprecipitation experiments with A454 showed that the mature GPI/b was not produced in the presence of monensin (Fig. 6 B, lane 2) . PMI-1 immunoprecipirated the pro-GPIIb at 130 kD (Fig. 6 B, lane 3 ) and 22C4 the GPIIIa at 100 kD (Fig. 6 B, lane 4) . These data support the hypothesis that glycosylation and carbohydrate processing is a prerequisite for the conversion of pro-GPIIb to GPIIb.
Mature GPIIb Form is Expressed on the Cell Surface While the Pro-GPIlb is an Intracellular Form
To assess whether both the pro-GPIIb and GPIIb were expressed at the surface of megakaryocytes, the cells were subjected to lactoperoxidase-catalyzed surface labeling followed by immunoprecipitation with A454. The results are shown in Fig. 7 . This antibody immunoprecipitated reduced electrophoretic bands corresponding to the mature form of GPIIb and GPIIIa from surface-labeled megakaryocytes (Fig. 7,  lane 2) . The presence of the pro-GPIIb form was simultaneously detected in metabolically labeled megakaryocytes (Fig.  7, lane 1) . Control experiments with surface-labeled platelets indicated that the GPI/b and GPIIIa of platelets and megakaryocytes were of similar molecular masses (Fig. 7,  lane 3) . These results suggest that only the mature GPIIb and GPIIIa forms are accessible at the cell surface.
Discussion
The present study indicates that human megakaryocytes produce platelet GPUb-IIIa. Previous studies using either enriched bone marrow megakaryocytes (23) or megakaryocytes from human committed megakaryocytes progenitor cells (11) have demonstrated the synthesis of GPIIb and GPIIIa in these cells. The source of megakaryocytes used in the present study was cryopreserved blood ofCML paticats. These sampies offer the distinct advantage in that large numbers of de- veloping megakaryocytes (20-100 × 1~) can be obtained for the study of the biosynthesis of platelet factors. Furthermore, these cells can be purified by fluorescence-activated cell (FAC) sorting to >90% homogeneity and exhibit a capacity to differentiate (4) . The present study has demonstrated that human megakaryocytes synthesize the glycoproteins IIb and l~a separately. No precursor form, common to both the GPIab and the GPIIIa, could be detected even during short time pulse-chase experiments. In contrast the a and 13 subunits of GPIlb were derived from the same precursor. Bray et al. have reported cell-free translation studies in the erythroblastic cell line, HEL, and obtained a similar biosynthetic system for the GPITo-IZIa (5). Thus, the GPIIb and GPIIIa are the end products of separate genes while a single gene codes for the ¢t and 13 subunits of GPIIb.
GPIIIa is synthesized as a single chain glycoprotein having an apparent molecular mass of 100 kD (reduced) or 90 kD (nonreduced). These values are similar to previously published molecular masses of the reduced and nonreduced forms of platelet GPIIIa. The protein did not exhibit detectable changes in its estimated molecular mass during pulsechase experiments over a 48-h period, suggesting that the oligosaccharide side chains added co-translationally are not further processed. In contrast, mature GPIIb derives from a posttranslational processing of a single polypeptide chain, the pro-GPIIb moiety, with an apparent molecular mass of 130 (reduced) or 120 (nonreduced) kD. This difference in molecular mass suggests that intrachain disulfide bonds influence the conformation of the nonreduced form of proGPIIb.
The precursor-product relationship between pro-GPIIb and GPIIb was established from the following observations: (a) immunoprecipitation of pro-GPIIb with PMI-1, a monoclonal antibody specific for the GPIIbct; (b) pulse-chase experiments showing the gradual disappearance of the precursor and the simultaneous production of the 0t and 13 subunits of GPIIb; (c) the acquisition of endo H resistance with time; and (d) the capacity of the precursor to interact with specific antibodies directed against GPIIbct and GPIIb13. This last observation confirmed that the reduced form of pro-GPIIb contains both GPIIb subunits. Thus, the transition between pro-GPIIb and mature GPIIb involves a posttranslational proteolytic event. The pulse-chase experiments indicate that the production of mature GPIIb is a slow process, 48 h being necessary for the total disappearance of the precursor.
GPIIb-IIIa is a glycoprotein and glycosylation influences its biosynthesis and expression at the cell surface. Tunicamycin, which inhibits N-glycosylation but not O-glycosylation, induces the formation of the aglycoforms of pro-GPIIb and GPIIIa, but mature GPIIb was not produced when its precursor was not glycosylated. The 120-kD form of pro-GPIIb synthesized in the presence of tunicamycin is most probably the nonglycosylated pro-GPIIb, as a similar nonglycosylated 120-kD pro-GPIIb can be identified in a cell-free translation mixture of megakaryocyte mRNA. Furthermore, the proGPIIb is sensitive to endo H and treatment with this enzyme yields a single polypeptidic chain of 120 kD. Similar results were obtained for GPIIIa. Both tunicamycin and endo H treatments generated a single electrophoretic band of 90 kD. This value is in agreement with that previously reported for the nonglycosylated form of GPIIIa synthesized by mRNA from the HEL cell line (5) and may well represent the fully deglycosylated form of GPIIIa. We were unable to immunoprecipitate the aglyco-form of GPIIIa in cell-free translation experiment with A454. A454 was raised against nonreduced GPIIb-IIIa and, as pointed out by Bray et al. (5), the translation product of the GPIIIa mRNA is not recognized by this type of antibody. Thus, it can be concluded that pro-GPIIb and GPIIIa contain N-linked oligosaccharides of the highmannose type. In contrast, mature GPIIb was endo H resistant, suggesting that the processing of the oligosaccharide side chains of this glycoprotein occurs in the Golgi cisternae. This is supported by the results of experiments in the presence of monensin. Monensin interferes with the intracellular transport and processing of glycoproteins. It has no effect on the production of glycosylated pro-GPIIb and GPIIIa, again suggesting that GPIIIa carbohydrates moieties are not processed. In contrast, the production of mature GPIIb was stopped, indicating that either monensin interferes with the proteolytic cleavage which transforms the pro-GPIIb into the two chain GPIIb, or that the processing of the N-linked highmannose side chains is a prerequisite in the precursor-product transition. The proteolytic cleavage occurred either before or after the passage through the Golgi system. This type of processing is not unique to the GPIIb and has also been described for the other proteins (10, 24). The pulse-chase kinetic analysis suggests that 1-3 h are necessary for processing the high-mannose oligosaccharide side chains of proGPIIb.
The present study gives some insight into the details of the biosynthesis of GPIIb and GPIIIa in human megakaryocytes. GPIIb-IIIa resembles the majority of the membrane glycoproteins in their pattern of N-linked oligosaccharide biosynthesis. Differences in the glycosylation of the two subunits have been identified. The glycosylation of GPIIIa occurs cotranslationally and the glycoprotein then undergoes no further processing. In contrast, the production of mature GPIIb is dependent upon the processing of the carbohydrate moiety and this is probably the rate-limiting step in GPIIb-IIIa production. The present study does not however determine whether GPIIIa associates with pro-GPIIb or solely with the mature form of GPIIb. These possibilities are now under investigation. The results obtained using surface-labeled megakaryocytes indicate that only the mature form of GPIIb is expressed at the cell surface. Experiments to demonstrate binding of fibrinogen to megakaryocyte were unsuccessful (our unpublished results). Thus the acquisition of the fibrinogen receptor activity may well occur postsynthetically during platelet formation.
